Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA by Lanford, R. E. et al.
Acute hepatitis A virus infection is associated with
a limited type I interferon response and persistence
of intrahepatic viral RNA
Robert E. Lanforda,b,1, Zongdi Fengc, Deborah Chaveza, Bernadette Guerraa, Kathleen M. Braskyb, Yan Zhoud,
Daisuke Yamanec, Alan S. Perelsone, Christopher M. Walkerd, and Stanley M. Lemonc
aDepartment of Virology and Immunology, Texas Biomedical Research Institute, and bSouthwest National Primate Research Center, San Antonio, TX
78227; cDivision of Infectious Diseases, Department of Medicine, Center for Translational Immunology, and the Lineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC 27599-7292; dCenter for Vaccines and Immunity, Research Institute at Nationwide Children’s Hospital, Columbus,
OH 43205; and eTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545
Edited* by Charles M. Rice, The Rockefeller University, New York, NY, and approved May 27, 2011 (received for review February 4, 2011)
Hepatitis A virus (HAV) is an hepatotropic human picornavirus that
is associated only with acute infection. Its pathogenesis is not well
understood because there are few studies in animal models using
modern methodologies. We characterized HAV infections in three
chimpanzees, quantifying viral RNA by quantitative RT-PCR and
examining critical aspects of the innate immune response including
intrahepatic IFN-stimulated gene expression. We compared these
infection profiles with similar studies of chimpanzees infected with
hepatitis C virus (HCV), an hepatotropic flavivirus that frequently
causes persistent infection. Surprisingly, HAV-infected animals
exhibited very limited induction of type I IFN-stimulated genes in
the liver compared with chimpanzees with acute resolving HCV
infection, despite similar levels of viremia and 100-fold greater
quantities of viral RNA in the liver. Minimal IFN-stimulated gene 15
and IFIT1 responses peaked 1–2 wk after HAV challenge and then
subsided despite continuing high hepatic viral RNA. An acute in-
flammatory response at 3–4 wk correlated with the appearance of
virus-specific antibodies and apoptosis and proliferation of hepa-
tocytes. Despite this, HAV RNA persisted in the liver for months,
remaining present long after clearance from serum and feces and
revealing dramatic differences in the kinetics of clearance in the
three compartments. Viral RNA was detected in the liver for sig-
nificantly longer (35 to >48 wk) than HCV RNA in animals with
acute resolving HCV infection (10–20 wk). Collectively, these find-
ings indicate that HAV is far stealthier than HCV early in the course
of acute resolving infection. HAV infections represent a distinctly
different paradigm in virus–host interactions within the liver.
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Hepatitis A virus (HAV) is a small, hepatotropic positive-strand RNA virus. Although it is classified among the
Picornaviridae, it differs in several important respects from most
other human picornaviral pathogens in having a very slow and
nonlytic replication cycle (reviewed in ref. 1). Several primate-
derived cell lines are permissive for infection by HAV, and in the
absence of extensive adaptation of the virus to cell culture, these
infections are typically noncytopathic. Despite this, HAV causes
only acute disease in humans and has never been documented to
establish long-term persistent infection within the liver (1–3).
However, relatively little is known about the pathogenesis of HAV
infections and how the virus is cleared from the liver as there has
been little impetus for research on hepatitis A since the de-
velopment of effective inactivated vaccines almost 2 decades ago.
The absence of long-term persistent HAV infection is well
documented by disappearance of the virus from isolated human
populations over time (4, 5) and differs dramatically from the
outcome of hepatitis C virus (HCV) infections, which persist for
life in the majority of persons (6). HCV is the cause of consid-
erable human morbidity and mortality. Like HAV, it is a positive-
strand RNA virus, albeit classified among the Flaviviridae. De-
spite significant differences, the replication strategies of these
viruses share a number of features, including the production of
double-stranded RNA (dsRNA), a potent inducer of innate im-
mune responses during the replication of their genomes by cy-
toplasmic membrane-bound replicase complexes. Moreover,
recent data indicate that both viruses have evolved similar
strategies to disrupt early innate immune responses involved in
the induction of IFN synthesis (reviewed in ref. 7). These simi-
larities in the biology of these viruses stand in marked contrast to
the differences in infection outcome and suggest that studies
comparing the early host responses to HAV and HCV might
provide unique insight into the role of innate immunity in the
control of intrahepatic infections by RNA viruses. Such studies
could provide important clues to the mechanisms underlying
HCV persistence.
Other than humans, chimpanzees (Pan troglodytes) represent
the only animal species permissive for both HAV and HCV in-
fection. Chimpanzee studies have provided a wealth of valuable
information concerning the pathogenesis of both acute and
chronic HCV infection (8). Similarly, chimpanzee studies carried
out in the 1970s revealed many features of the natural history of
hepatitis A and provided an important scientific platform for
vaccine development (9–12). Such studies have not been done in
recent years, however, and there are no studies using contem-
porary molecular and immunological techniques on which a de-
tailed comparison of the early events in HAV and HCV infection
can be made. The genetic, physiological, and immunological
similarities of chimpanzees to humans make them unique models
of human infectious diseases, and the only animal species in
which this kind of comparative study can be done.
Here, we describe the early innate immune responses to HAV
infection in three chimpanzees. We compare virologic events and
intrahepatic host transcriptional responses to historical data
from chimpanzees undergoing acute, self-limited HCV infection.
We show that viral RNA is much more abundant in the HAV-
infected liver, despite similar levels of viremia, and persists for
much longer than HCV RNA in animals with acute resolving
HCV infection. Surprisingly, we find a paucity of type I IFN
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responses in the HAV-infected liver, which is in marked contrast
to the robust intrahepatic type I IFN-stimulated gene (ISG) re-
sponse that typifies both acute and persistent HCV infection in
chimpanzees and humans (13–16).
Results
HAV Persists in the Liver Following Its Clearance from Serum and
Feces. Two adult chimpanzees, 4x0293 and 4x0395, were infected
by i.v. challenge with the HM175 strain of HAV. A third animal
(4x0396) was infected by natural exposure while cohoused with
4x0293. HAV RNA was detected in liver, feces, and serum within
2 d of challenge, reaching peak levels in all three compartments
by weeks 2–3 (Fig. 1). Peak viremia ranged from 3 to 10 × 106
genome equivalents (GE)/mL of serum and was similar in
magnitude to peak HCV viremia in a cohort of eight chimpan-
zees with acute resolving infection (Fig. 2A). Shedding of HAV
into the feces peaked coincidently with viremia, reaching a max-
imum of 4 × 108 GE/g of feces in 4x0395 (Fig. 1). HCV is not
found in feces, possibly because it is not transported vectorially
from the hepatocyte into billiary canaliculi like HAV (10, 17) or
because its virion contains a lipid envelope and is not stable in
bile. HAV RNA also peaked in the liver at weeks 2–3 (Fig. 1),
reaching levels up to 9 × 106 GE/μg total liver RNA, ∼100-fold
higher than HCV RNA in acute resolving infections (Fig. 2A).
HAV RNA levels were thus much higher in liver than HCV
RNA levels, whereas the magnitude of viremia was similar in the
two infections.
HAV was cleared rapidly from the blood beginning ∼3 wk
after infection. Serum HAV RNA declined with a mean half-life
(t1/2) of 1.6 d and was no longer detectable by weeks 6–8. Al-
though fecal shedding of viral RNA declined by more than
a factor of 104 during this period, clearance was slower from
feces (mean: t1/2 3.8 d). Viral RNA was detected in feces by
sensitive RT-PCR assay as late as 20 wk postinfection in 4x0395,
12 wk after clearance of viremia (Fig. 1). Remarkably, the
amount of HAV RNA within the liver declined very slowly
(mean: t1/2 8.9 d). Whereas fecal viral RNA declined 1,000-fold
between weeks 2–4 in 4x0293, HAV RNA in the liver decreased
only 2.5-fold. During the first 10 wk, viral RNA in the liver de-
clined by only 10-fold and was still detectable at 48 wk. Two-
photon fluorescent microscopy revealed the presence of HAV
capsid antigen in ∼20% of cells in the liver at 3 wk and in ∼5% at
week 10; these cells were distributed in a patchy fashion with no
particular concentration in periportal or centrilobular regions
(Fig. S1A). Rare antigen-positive cells were present at week 27.
dsRNA could be identified by antibody labeling in ∼10% of cells
at week 3 and in ∼1% of cells at 10 wk (Fig. S1B), suggesting that
HAV replicase complexes may persist in a small proportion of
cells. A single follow-up biopsy at 72 wk was negative by RT-
PCR. This pattern of intrahepatic viral RNA persistence was
observed in all three animals. Although the t1/2 of HAV RNA in
serum (1.6 d) is similar to that reported for HCV following the
initial elevation of alanine aminotransferase (ALT) activity (1.8
d) (18), the persistence of HAV RNA in the liver contrasts
sharply with what is typically observed in chimpanzees with acute
resolving HCV infection, where viremia and hepatic viral RNA
are cleared coincidently, typically within 10–20 wk of infection
(Fig. S1C) (13, 19). The mean half-life of viral RNA in the liver
of HCV-infected chimpanzees was 4.2 d, compared with 8.9 d for
HAV (Fig. S1C).
The earliest evidence of host control of the infection, reflected
in initial declines of viral RNA in all three compartments, oc-
curred at weeks 3–4, coincident with or slightly before peak
elevations in serum ALT and the appearance of anti-HAV
antibodies (Fig. 1). Anti-HAV antibodies have potent virus-
neutralizing activity and are protective against reinfection (20),
but appeared to have little impact on hepatic viral RNA copy
numbers in these animals. Although fecal shedding of the virus
initially declined in parallel with the drop in viremia, 4x0293 and
4x0395 demonstrated a biphasic pattern of viral clearance from
feces, with a transient rebound in fecal RNA shedding at weeks
Fig. 1. Persistence of hepatic viral RNA in HAV-infected chimpanzees. Two
chimpanzees (4x0293 and 4x0395) were inoculated intravenously using 5,000
chimp infectious doses of HAV HM175 containing 3 × 107 GE (a gift of Robert
Purcell, National Institutes of Health, Bethesda, MD). A third animal (4x0396)
became infected naturally while housed with infected animals. The exact day
of natural infection was not known, but alignment of the three infection
profiles by peak viremia, seroconversion for HAV IgM, and peak ALT sug-
gests that infection of 4x0396 occurred 4 wk after inoculation of his cage
mate, 4x0293; thus, this week was designated as week 1 for 4x0396. HAV
RNA was quantified by TaqMan RT-PCR assays. The limit of detection varied
in each compartment due to differences in the samples processed for the
assay: serum (red line: linear limit of detection 103 GE/mL serum), liver (green
line: linear limit of detection 101 GE/μg total RNA), and feces (blue line: linear
limit of detection 5 × 103 GE/gm feces). Samples from all three compartments
were analyzed throughout the study, but only positive samples are shown in
the line graphs. The number to the right of each line represents the calcu-
lated t1/2 for clearance from that compartment. ALT levels are indicated by
the gray shaded area. IgM anti-HAV and total anti-HAV was determined by
ELISA and are shown as positive or negative (+ or −) at the top of the graphs.
The duration of follow-up differs for each animal.
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8–10 (Fig. 1). A similar pattern may have occurred in 4x0396.
This was not matched by quantitative changes in RNA copy
numbers in serum or liver of any animal, suggesting the possi-
bility of an independent gastrointestinal replication compart-
ment as proposed previously (21).
Maximum ALT elevations were somewhat greater than in
acute resolving HCV infection (Fig. 2B) and coincided with
a massive periportal mononuclear cell infiltrate that extended
into the parenchyma at weeks 3 and 4 (Fig. 2C and Fig. S2 A–D).
The inflammatory infiltrate was associated with severe hepato-
cyte swelling and necrosis. Numerous cells (up to 40% in se-
lected fields by week 4) stained positively for activated caspase 3,
a marker of apoptosis (Fig. 2D and Fig. S2 E–H). Many of the
caspase 3-positive cells were hepatocytes (Fig. S2M); however,
others appeared to be in sinusoidal spaces and resembled lym-
phocytes. Ki67, a marker of cell proliferation, was expressed by
numerous hepatocytes (Fig. S2N) and infiltrating mononuclear
cells at weeks 3–4 (Fig. 2E and Fig. S2 I–L). The number of
proliferating cells decreased markedly by weeks 6 and 10.
Collectively, these data indicate that an acute inflammatory
host response develops 3–4 wk into the infection, following
a clinically silent early infection phase several weeks in length
that is marked by robust replication of virus within the liver.
Appearance of anti-HAV antibodies has relatively little impact
on the intrahepatic viral load. Viral RNA copy numbers decline
slowly over a period of months in parallel with decreasing
numbers of hepatocytes staining positive for HAV antigen. Viral
RNA and HAV antigen indicative of assembled virus capsids
(22) persist long after ALT elevations have returned to normal
and hepatic inflammation has resolved.
Intrahepatic Transcriptional Responses to HAV Infection. We exam-
ined the intrahepatic transcriptional response toHAV infection in
serial liver biopsies from 4x0293, 4x0395, and 4x0396 using Affy-
metrix whole-genome microarrays. This revealed few changes in
transcript abundance and no up-regulated gene common to all
three animals 2 d after infection (Dataset S1), at which time the
HAVRNA copy number exceeded >103 GE/μg RNA in the liver.
Two-dimensional clustering and heat map analysis of the entire
data set confirmed that there were relatively few consistent
changes in the hepatic transcriptome early in the course of HAV
infection (Fig. S3). Importantly, there were more differences be-
tween the various preinfection biopsies from the animals than
between the preinfection and 2-wk biopsy from 4x0293 (when
there were >105 HAV GE/μg RNA in the liver).
The first evidence of an IFN response occurred at week 1
when low-level increases in ISG15 transcripts appeared in both
4x0293 and 4x0395. These were accompanied by similar small
increases in other type I IFN-regulated genes, such as MX1,
IFIT1 (ISG56), IFIT3, and IFI6 in 4x0293. However, these and
other type I ISGs were not induced in 4x0395 until week 2, even
though viral RNA copy numbers exceeded 105 in the liver at
week 1. This paucity of type I IFN-induced ISG expression early
in infection contrasts sharply with prior studies of acute resolving
HCV infection, in which these genes are induced by day 2 of
infection and at much higher levels (13, 15). Fig. 3 (see also Fig.
S4) compares the responses of 16 selected type I IFN-responsive
genes in the HAV-infected animals and in an animal with acute
resolving HCV infection (4x0296). Most of these ISG transcripts
were up-regulated to a minimal degree and for only a few weeks
Fig. 2. Comparative features of acute HAV and acute resolving HCV in-
fection in the chimpanzee. (A) Maximum viral RNA copy numbers in liver
tissue (GE/μg total RNA) and serum (GE/mL). HCV infections were with ge-
notype 1 (open circle) or genotype 3 (solid circle, 4x0296) virus. Dashed lines
indicate mean values. (B) Maximum serum ALT activities. The shaded areas at
the bottom indicate the mean baseline ALT activity plus one and two SDs. (C–
E) Mononuclear cell infiltration, cell death, and proliferation in acute HAV
infection. Formalin-fixed, paraffin-embedded liver tissue obtained 4 wk after
HAV challenge (animal 4x0395) was (C) stained with hematoxylin and eosin,
(D) immunostained with antibody to activated caspase 3 as a marker of ap-
optosis, or (E) labeled with antibody to Ki67 as a marker of cell proliferation.
Liver tissue samples from preinfection and weeks 3, 4, and 10 after infection
are shown in Fig. S2.
Fig. 3. Intrahepatic ISG responses determined by whole-genome microarray analysis. Total RNA was extracted from liver biopsies collected at the times
indicated from animals with acute HAV infection (4x0293 and 4x0395) or acute resolving HCV infection (4x0296, genotype 3) and subjected to Affymetrix
GeneChip (U133 Plus 2.0) analysis. Numbers represent the fold-change in the Affymetrix signal from uninfected baseline samples. CXCL10 and ISG20
responses, which are known to be driven by IFN-γ as well as by type I IFN-α/β, are shown in red. Viral RNA copy numbers in liver tissue (GE/μg total RNA) are
represented by the shaded area. The results of individual animals are presented in Fig. S4, and results from a second HCV-infected animal are shown in Fig. S5.
The entire Affymetrix data set from HAV-infected chimpanzees is shown in Dataset S1.









in the HAV-infected animals despite 100-fold higher levels and
much longer persistence of viral RNA in the liver (Fig. 3). The
two ISGs that were up-regulated over 10-fold, CXCL10 and
ISG20, are genes that are also responsive to type II IFN (23). In
HCV infection, all of the ISGs were highly up-regulated for as
long as HCV RNA was present (Fig. 3 and Fig. S5).
Despite the minimal expression of type I IFN-stimulated
genes, many other genes became transcriptionally activated in
the liver at weeks 3–4 with the onset of inflammation. A total of
3,864 genes were up- or down-regulated twofold (P = 0.02) or
more (detailed results are presented in Dataset S1). Affymetrix
results from biopsies taken during this phase of the infection
clustered together and were distinguished by the induction of
genes stimulated by IFN-γ or involved in B-cell development
(Fig. S3). Ingenuity Pathway Analysis confirmed remarkable
activation of genes involved in B-cell development in all three
HAV-infected animals (Table S1). These included numerous Ig
genes and CXCL13, a chemokine involved in recruitment of
B cells to the liver that was highly up-regulated (20- to 100-fold)
in all three animals. Ig genes including heavy chains A, G, and M
and light chains λ and κ were highly induced at 3–4 wk in all
animals. Some remained induced in 4x0395 for up to 26 wk af-
ter infection. Many T-cell–associated transcripts were also up-
regulated at weeks 3–4, including CD3G, CD3D, granzyme B,
and perforin (Table S1). However, transcriptional responses as-
sociated with these adaptive immunity genes declined significantly
after week 6, well before the elimination of viral RNA from the
liver. Animals with acute HCV infection generally exhibit mini-
mal activation of these gene sets, possibly reflecting less lym-
phocytic infiltration of the liver (13, 15). Lymphocyte-associated
transcripts are often undetectable, even though it is well estab-
lished that T-cell responses resolve HCV infection (24, 25).
We validated the microarray results by comparing them with
quantitative RT-PCR (qRT-PCR)measurements of ISG15 and -4
other gene transcripts in the liver, noting a high level of correlation
for each (Table S2). We also used qRT-PCR to compare ISG15
transcriptional responses in the three HAV-infected animals and
a panel of eight chimpanzees with acute resolving HCV infection.
Maximum increases in hepatic ISG15 transcriptswere about 4-fold
in the HAV-infected chimpanzees, compared with >256-fold in
acute HCV infection (Fig. 4A). This large difference in the mag-
nitude of ISG15 induction is remarkable given that the viral RNA
copy numbers were on average about 100-fold less in the HCV
compared with HAV-infected animals (Fig. 2A). Immunohisto-
chemical stains demonstrated robust ISG15 expression as early as
1 wk after HCV infection, with virtually every hepatocyte staining
positive (Fig. 4B). In contrast, much lower levels of ISG15 ex-
pressionwere evident inHAV-infected liver where ISG15 staining
occurred in a patchy distribution of mostly mononuclear cells and
was not present in most hepatocytes (Fig. 4B).
Discussion
Collectively, the data presented here reveal that HAV is a re-
markably stealthy virus, with infection eliciting only a very limited
type I IFN response within the liver. This minimal ISG response
differs dramatically from what is observed in HCV infection (13–
16) and comes as a surprise, given that HAV causes only acute
disease whereas HCV infection typically persists and frequently
causes chronic hepatitis. We have previously concluded that
intrahepatic ISG responses are maximally induced in HCV-
infected chimpanzees, even at relatively low levels of viremia (13,
14, 26, 27). The level of induction of type I ISGs during acuteHCV
infection appears to be of similar magnitude in self-limited re-
solving infections, such as those described here, and in those that
become persistent (15, 19). Such responses do not occur in acute
hepatitis A, despite the fact that viral RNA abundance is 100-fold
greater within the liver than in acute hepatitis C (Fig. 2A) and that
dsRNA, a potent inducer of IFN responses, can be demonstrated
in up to 10%of hepatocytes (Fig. S1A). Two of the animals that we
studied, 4x0293 and 4x0395, were infected by i.v. inoculation, an
unusual route for HAV transmission in humans. However, 4x0396
became infected naturally, presumably by fecal-oral transmission
while caged with 4x0293, and demonstrated a similar paucity of
type I ISG responses. We conclude that low-level hepatic ISG
responses typify HAV infection in the chimpanzee. Given that
humans and chimpanzees are closely related phylogenetically,
and that HAV infection in the chimpanzee otherwise accurately
models human infection (9–12), type I IFN responses are likely to
be similarly muted in humans.
Viral RNAs are sensed in hepatocytes by the cytosolic helicases,
retinoic acid-inducible gene I (RIG-I) and melanoma differenti-
ation-associated gene 5 (MDA5), or by Toll-like receptor 3
(TLR3), which is expressed in an endosomal compartment
(reviewed in ref. 28). This activates signaling pathways that lead to
the phosphorylation of IFN-regulatory factor 3 (IRF-3) and type I
IFN synthesis. In HCV-infected cells, this signaling is disrupted by
the major viral protease, NS3/4A, which efficiently cleaves mito-
chondrial antiviral signaling protein (MAVS; also known as IPS-1,
VISA, orCardif), an essential adaptor protein forRIG-I, as well as
by the TIR-domain–containing adaptor inducing IFN-β (TRIF;
Fig. 4. Comparative analysis of ISG15 expression in HAV- and HCV-infected
chimpanzees. (A) ISG15 transcript levels, quantified by TaqMan qRT-PCR and
normalized to GAPDH transcript abundance, in liver tissue from (Left) three
chimpanzees with acute HAV infection versus (Right) eight animals with acute
resolving HCV infection. Results shown represent the fold-change from pre-
infection biopsy tissue. (B) Immunohistochemical staining for ISG15 expressed
in liver tissue before and 1–4 wk after challenge with HAV (Left panels:
4x0395) or HCV (Center and Right panels: 4x0313 and 4x0295). Chimpanzee
4x0313 was treated with the immunosuppressive agent FK506 and had no
evidence of an adaptive immune response at the time of biopsy (4 wk); this
animal is not included among the data shown in Figs. 2 A and B and 4A.
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otherwise known as TICAM-1), an essential TLR3 adaptor protein
(29–34). The robust expression of ISGs within the HCV-infected
liver, both in humans and in chimpanzees, is thus somewhat para-
doxical and not well explained, given the capacity of the virus to
disrupt these signaling pathways. One possibility is that infected
hepatocytes are sensed by TLR7 expressed in plasmacytoid den-
dritic cells (pDCs) (35), professional IFNproducers that account for
most type I IFN in many viral infections.
Because HAV, like HCV, replicates its genome through
a dsRNA intermediate and dsRNA is readily detected in the
HAV-infected liver (Fig. S1A), the data presented here indicate
that HAV must also possess potent mechanisms to disrupt IFN
synthesis. This is supported by in vitro studies that show that
HAV infection blocks the capacity of superinfecting viruses to
induce type I IFN through the RIG-I/MDA5 pathway (36, 37).
We have shown that this is due to the HAV 3ABC protease,
which is directed to the mitochondrial membrane where it
cleaves MAVS (36). Recent data also indicate that the 3CD
protease-polymerase processing intermediate disrupts TLR3
signaling by directing the cleavage of TRIF (37). HAV and HCV
thus have evolved in a remarkably congruent fashion to target
these signaling pathways and disrupt their ability to induce type I
IFN synthesis. HAV must have an additional advantage over
HCV, however, to account for the dramatic difference that we
have demonstrated in the IFN response to acute infection. Un-
like enveloped viruses, the activation of pDCs by picornaviruses
appears to require the presence of anti-viral antibodies (38, 39).
Although the pDC response to HAV has not been studied,
the weak induction of ISGs by HAV could reflect a failure of
pDCs to sense infection. This cannot be explained entirely by an
absence of antibody, however, as IgM anti-HAV appeared by
week 3 (Fig. 1) without a concomitant increase in ISG expres-
sion. Luminex assays for serum IFN-α in the HAV-infected
chimpanzees revealed a transient and minor elevation at week 2.
This was matched by low-level fluctuating increases (up to ap-
proximately threefold) in IFN-α, IFN-β, and IL28 transcripts in
the liver of 4x0395 during the first 3 wk of infection. In both
cases, positive results were near the limit of detection, but
nonetheless suggestive of induction and then active suppression
of type I IFN.
A second major surprise was how long HAV RNA persisted in
the liver of these animals following its clearance from both feces
and serum (Fig. 1). Viral RNA was reported recently to be
present in the liver of cynomolgous monkeys as late as 9 wk after
experimental HAV infection (40, 41), but its continued presence
beyond 46 wk in the chimpanzee (Fig. 1) was unexpected and
represents another major difference from acute resolving hepa-
titis C. In acute resolving HCV infection, viral RNA is typically
cleared by 10–20 wk of infection (Fig. S1C). It is difficult to know
whether the persistence of HAV RNA reflects ongoing viral
replication. The antigen that we identified in scattered cells as
late as 10 wk after challenge (Fig. S1A) is conformation-de-
pendent and indicative of assembled HAV capsids. In early
studies, HAV particles were found within resident hepatic
macrophages (Kupffer cells) (42), and thus the RNA could
possibly represent viral particles trapped in Kupffer cells. How-
ever, such long-term persistence of a positive-strand RNA virus
without some level of replication would be unprecedented. The
detection of dsRNA in a very small number of cells at 10 wk (Fig.
S1A) suggests the possibility of ongoing replication, but addi-
tional studies are needed to confirm this. A continuing low level
of viral replication within the liver could be relevant to the
pathogenesis of relapsing hepatitis A, which occurs in up to 20%
of patients in the months following apparent resolution of acute
hepatitis (43). It could also contribute to the persistence of an-
tibody to HAV following infection.
Although viral RNA copy numbers peaked at 3–4 wk in blood,
feces, and liver, the kinetics of decline in these compartments
were dramatically different. Viremia rapidly declined to un-
detectable levels following the appearance of antibody, suggesting
that neutralizing antibody plays a major role in clearing viremia
(20). Transcriptome analyses indicated that B-cell responses are
highly induced at this time (Table S1). Fecal shedding of virus was
initially reduced in parallel with viremia (Fig. 1), but then fol-
lowed an unexplained biphasic decline in at least two of three
animals. Viral RNA declined much more slowly in the liver and
was still highly abundant at the time that it disappeared from
feces. Exactly how and when HAV is finally cleared from the liver
remains unknown. Neutralizing antibody may halt spread to un-
infected cells, whereas the residual infected cells may be slowly
cleared by natural turnover or T-cell activity. Similar mechanisms
may be involved in the clearance of hepatocytes containing re-
sidual hepatitis B virus covalently closed circular DNA after vi-
remia is cleared during acute infection (44).
Blunted production of type I IFN could influence the strength
and effectiveness of T-cell immunity that is important for control
of HAV infection. Type I IFN acts directly on CD8+ T cells to
promote differentiation and/or acquisition of effector functions
(45), although the requirement for this cytokine may be patho-
gen-dependent (46, 47). Our data suggest that the chimpanzee
model of human HAV infection will be of general importance
in defining the relationship between early innate and adaptive
immune responses.
One of themost striking conclusions to come from these studies
is that there is much remaining to be learned about hepatitis A
infections and HAV, a virus that has been largely neglected by
the research community in recent years. Comparative studies with
HCV are long overdue and are likely to provide insight into the
mechanisms of viral persistence in chronic hepatitis C.
Materials and Methods
Complete methods are presented in SI Materials and Methods, including
details concerning the care of chimpanzees at the SouthwestNational Primate
Research Center (48) and the HAV and HCV infections. The methods for
transcriptome analysis using Affymetrix microarrays (accession no. GSE27850;
SI Materials and Methods) and ABI TaqMan assays (26, 27) and for immuno-
histochemical staining of liver sections (49) have been published previously.
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